Does Rallies show 13F holders for GLUE?

Yes. Rallies tracks hedge fund and 13F ownership data for GLUE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is GLUE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GLUE. It does not provide personalized investment advice.

GLUE (Monte Rosa Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Monte Rosa Therapeutics, Inc. Common Stock (GLUE) is a publicly traded Healthcare sector company. As of May 21, 2026, GLUE trades at $18.62 with a market cap of $1.52B and a P/E ratio of 0.00. GLUE moved +6.09% today. Year to date, GLUE is +29.51%; over the trailing twelve months it is +348.32%. Its 52-week range spans $3.50 to $25.77. Analyst consensus is strong buy with an average price target of $32.80. Rallies surfaces GLUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns GLUE stock?

Hedge funds tracked by Rallies that own GLUE include Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Monte Rosa Therapeutics, Inc. Common Stock.

GLUE Key Metrics

Key financial metrics for GLUE
Metric	Value
Price	$18.62
Market Cap	$1.52B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$25.77
52-Week Low	$3.50
Volume	6
Avg Volume	0
Revenue (TTM)	$75.62M
Net Income	$-72.70M
Gross Margin	0.00%

Top Hedge Funds Holding GLUE

Mangrove Partners holds 13.71K shares of GLUE, changed +0.00% as of Mar 31, 2026.

Latest GLUE News

Monte Rosa Therapeutics Posts $0.45 Q1 Loss, Misses Revenue Estimates — May 7, 2026
Monte Rosa Therapeutics Cuts CRP by 85%, Eyes H2 2026 Phase 2 Trials — May 7, 2026
Monte Rosa Secures J&J Supply for Phase 2 MRT-2359/Apalutamide mCRPC Trial — Mar 16, 2026
Monte Rosa Reports 100% PSA Response in AR-Mutant mCRPC; Phase 2 Set for Q3 2026 — Feb 24, 2026
Monte Rosa Prices $300M Offering, Shares Surge 45% on Phase I Data — Jan 9, 2026

Recent GLUE Insider Trades

Warmuth Markus sold 5.47K (~$103.45K) on May 1, 2026.
Warmuth Markus sold 8.00K (~$141.12K) on Apr 14, 2026.
Nickson Philip sold 5.84K (~$103.41K) on Apr 9, 2026.

GLUE Analyst Consensus

7 analysts cover GLUE: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.80.

Common questions about GLUE

Who owns GLUE stock?: Hedge funds tracked by Rallies that own GLUE include Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Monte Rosa Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for GLUE?: Yes. Rallies tracks hedge fund and 13F ownership data for GLUE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is GLUE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GLUE. It does not provide personalized investment advice.